Similar articles

• [Polyneuropathies and dysglobulinemias].

  Ferrer S, Jiménez C. Ferrer S, et al. Rev Med Chil. 1994 Apr;122(4):448-53. Rev Med Chil. 1994. PMID: 7809541 Review. Spanish.
• Long-term effect of rituximab in anti-mag polyneuropathy.

  Benedetti L, Briani C, Franciotta D, Carpo M, Padua L, Zara G, Zambello R, Sormani MP, Mancardi GL, Nobile-Orazio E, Schenone A. Benedetti L, et al. Neurology. 2008 Nov 18;71(21):1742-4. doi: 10.1212/01.wnl.0000335268.70325.33. Neurology. 2008. PMID: 19015493 No abstract available.
• [Developmental trends in neuroimmunology. 1: Principles, immuno-components, immunogenetics, contributions of virology].

  Meyer-Rienecker HJ. Meyer-Rienecker HJ. Nervenarzt. 1984 Dec;55(12):617-24. Nervenarzt. 1984. PMID: 6441125 German. No abstract available.
• [In-vitro and in-vivo studies on the selective immunoadsorption treatment of neurological diseases].

  Heininger K. Heininger K. Schriftenr Neurol. 1993;33:1-91. Schriftenr Neurol. 1993. PMID: 8327864 Review. German. No abstract available.
• [Treatment of chronic immune-mediated polyneuropathies. State of the art and perspectives].

  Léger JM, Chassande B. Léger JM, et al. Ann Med Interne (Paris). 2000 May;151 Suppl 1:1S19-23. Ann Med Interne (Paris). 2000. PMID: 10896984 Review. French.